Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 107-113

  Morawietz, Henning ^a   Goettsch, Winfried ^a   Brux, Melanie ^a   Reimann, Manja ^a   Bornstein, Stefan R ^a   Julius, Ulrich ^a   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Atherosclerosis; Endothelial function; Gene expression; Hypercholesterolemia; Lipoprotein apheresis

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; APHERESIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN APHERESIS; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VASOPROTECTION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; BLOTTING, WESTERN; CELLS, CULTURED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; TREATMENT OUTCOME; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84872856890     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.013     Document Type: Article

References (43)

1. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012 Feb 16, [Epub ahead of print].
2. Thompsen J., Thompson P.D. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
3. Thompson G.R. Lipoprotein apheresis. Curr Opin Lipidol 2010, 21:487-491.
4. Koziolek M.J., Hennig U., Zapf A., et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Apher Dial 2010, 14:143-152.
5. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
6. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
7. Morimoto S., Yano Y., Maki K., Sawada K., Iwasaka T. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Am J Nephrol 2007, 27:643-648.
8. Reimann M., Julius U., Haink K., et al. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 2010, 213:212-217.
9. Reimann M., Prieur S., Lippold B., et al. Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atheroscler Suppl 2009, 10:39-43.
10. Sawamura T., Kume N., Aoyama T., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386:73-77.
11. Mitra S., Goyal T., Mehta J.L. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011, 25:419-429.
12. Yoshimoto R., Fujita Y., Kakino A., Iwamoto S., Takaya T., Sawamura T. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011, 25:379-391.
13. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001, 104:1767-1772.
14. Stielow C., Catar R.A., Muller G., et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006, 344:200-205.
15. Catar R.A., Muller G., Heidler J., Schmitz G., Bornstein S.R., Morawietz H. Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res 2007, 39:801-805.
16. Muller G., Catar R.A., Niemann B., et al. Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins. Exp Biol Med (Maywood) 2006, 231:766-771.
17. Niemann B., Rohrbach S., Catar R.A., Muller G., Barton M., Morawietz H. Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells. Biochem Biophys Res Commun 2005, 334:747-753.
18. Mehta J.L., Sanada N., Hu C.P., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007, 100:1634-1642.
19. Morawietz H. LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice. Circ Res 2007, 100:1534-1536.
20. Inoue K., Arai Y., Kurihara H., Kita T., Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 2005, 97:176-184.
21. Eichhorn B., Muller G., Leuner A., Sawamura T., Ravens U., Morawietz H. Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet. Cardiovasc Res 2009, 82:493-502.
22. Muller G., Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid Redox Signal 2009, 11:1711-1731.
23. Cattin L., Petrucco A., Cazzolato G., et al. Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells. ASAIO J 1997, 43:209-213.
24. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
25. Duerrschmidt N., Stielow C., Muller G., Pagano P.J., Morawietz H. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J Physiol 2006, 576:557-567.
26. Gordon S.M., Hofmann S., Askew D.S., Davidson W.S. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab 2011, 22:9-15.
27. Aoyama T., Fujiwara H., Masaki T., Sawamura T. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J Mol Cell Cardiol 1999, 31:2101-2114.
28. Hirata K., Miki N., Kuroda Y., Sakoda T., Kawashima S., Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995, 76:958-962.
29. Lee W.J., Ou H.C., Hsu W.C., et al. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J Vasc Surg 2010, 52:1290-1300.
30. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995, 270:319-324.
31. Tsurumi-Ikeya Y., Tamura K., Azuma K., et al. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol 2010, 30:1058-1065.
32. Goettsch W., Gryczka C., Korff T., et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol 2008, 214:491-503.
33. Morawietz H., Rohrbach S., Rueckschloss U., et al. Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest 2006, 36:705-712.
34. Patschan D., Patschan S., Henze E., Wessels J.T., Koziolek M., Muller G.A. LDL lipid apheresis rapidly increases peripheral endothelial progenitor cell competence. J Clin Apher 2009, 24:180-185.
35. Pulawski E., Mellwig K.P., Brinkmann T., Kleesiek K., Horstkotte D. Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin. Ther Apher 2002, 6:229-233.
36. Empen K., Otto C., Brodl U.C., Parhofer K.G. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apher 2002, 17:38-43.
37. Mellwig K.P. Heparin-induced extracorporeal low-density lipoprotein precipitation. Ther Apher Dial 2003, 7:365-369.
38. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
39. Utsumi K., Kawabe M., Hirama A., et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2007, 377:198-200.
40. Khan B.V., Parthasarathy S.S., Alexander R.W., Medford R.M. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995, 95:1262-1270.
41. Li D., Chen H., Romeo F., Sawamura T., Saldeen T., Mehta J.L. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002, 302:601-605.
42. Morawietz H., Erbs S., Holtz J., et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006, 114:I296-I301.
43. Morawietz H., Rueckschloss U., Niemann B., et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999, 100:899-902.